← All trials
NCT07207057
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2025
- Primary completion
- May 31, 2031
- Completion date
- Jul 31, 2031
- First posted
- Oct 3, 2025
- Last posted
- Oct 3, 2025
- Enrollment
- 1200
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- Michael J. Fox Foundation for Parkinson's ResearchCollaborator
- University of LondonOfficial
- Medical Research CouncilCollaborator
- Van Andel Research InstituteCollaborator
- National Institute for Health Research, United KingdomCollaborator
- Newcastle UniversityOfficial
- Newcastle UniversityCollaborator
- Cure Parkinson's TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.